Ravulizumab 1.1g/11ml solution for infusion vials
NHS hospitals in England used £102,882,479 of indicative cost of Ravulizumab 1.1g/11ml solution for infusion vials in the 12 months to July 2026, about 0.4% of all hospital medicines spend. That is down 6.9% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ravulizumab 1.1g/11ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ravulizumab 1.1g/11ml solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Leeds Teaching Hpls Nhs Trust | £42,233,961 |
| King's College Hpl Nhs Foundation Trust | £29,518,896 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £3,290,958 |
| Manchester University Nhs Ft | £2,740,954 |
| University College London Foundation Tr | £2,459,908 |
| Guy's & St Thomas' Nhs Foundation Trust | £2,293,698 |
| Aintree University Hospital Nhs Ft | £1,844,931 |
| Cambridge Univ Hosp Nhs Foundation Trust | £1,396,164 |
| Barts Health Nhs Trust | £1,213,333 |
| Sheffield Teaching Hospitals Nhs Trust | £1,146,849 |
The primary-care picture
Ravulizumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Ravulizumab medicine page.